The board of directors of Medtronic plc on Friday, March 5, 2021 approved the fiscal year 2021 fourth quarter cash dividend of $0.58 per ordinary share, representing a 7.4 percent increase over the prior year. This quarterly declaration is consistent with the dividend announcement made by the company in May 2020.  Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual ...

The board of directors of Medtronic plc (NYSE: MDT) on Friday, March 5, 2021 approved the fiscal year 2021 fourth quarter cash dividend of $0.58 per ordinary share, representing a 7.4 percent increase over the prior year. This quarterly declaration is consistent with the dividend announcement made by the company in May 2020.  Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 43 consecutive years. The dividend is payable on April 16, 2021 to shareholders of record at the close of business on March 26, 2021 .

About Medtronic
Medtronic plc ( www.medtronic.com ), headquartered in Dublin, Ireland , is among the world's largest medical technology, services and solutions companies – alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 90,000 people worldwide, serving physicians, hospitals and patients in more than 150 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Contacts:



Erika Winkels

Ryan Weispfenning

Public Relations

Investor Relations

+1-763-526-8478

+1-763-505-4626

Cision View original content to download multimedia: http://www.prnewswire.com/news-releases/medtronic-announces-cash-dividend-for-fourth-quarter-of-fiscal-year-2021-301241111.html

SOURCE Medtronic plc

News Provided by PR Newswire via QuoteMedia

Leveljump Healthcare Strengthens Board of Directors

Leveljump Healthcare Strengthens Board of Directors

LevelJump Healthcare Corp. (TSXV: JUMP) (OTCQB: JMPHF) (FSE: 75J) ("Leveljump" or the "Company"), a Canadian leader in B2B telehealth solutions, is pleased to announce new additions to its board of directors and its advisory board.

Gary Prihar - Director

Keep reading... Show less
ALR Technologies and Infinovo Sign Memorandum of Understanding to Manufacture World's First CGM for Diabetic Pets

ALR Technologies and Infinovo Sign Memorandum of Understanding to Manufacture World's First CGM for Diabetic Pets

ALR Technologies ("ALRT" or the "Company") (OTCQB: ALRT), the diabetes management company, is pleased to announce the signing of a Memorandum of Understanding ("MOU") with Infinovo Medical Co. Ltd for a global supply agreement of their P3 Continuous Glucose Monitor (CGM) for use by ALRT in the animal health sector.

Under the terms of the MOU, ALR Technologies and Infinovo will collaborate to integrate Infinovo's P3 CGM with ALRT's proprietary GluCurve platform. The Company expects to begin testing the GluCurve Pet CGM in veterinary clinics in late December 2021 or early January 2022. The testing is scheduled to complete by the end of February 2022.

Keep reading... Show less

Medtronic Hugo robotic-assisted surgery system receives Health Canada licence, further enabling access to robotic-assisted surgery in Canada

Medtronic Canada ULC, a subsidiary of Medtronic plc (NYSE: MDT), the world's leading medical technology company, announced it has received a Health Canada licence for the Hugo™ robotic-assisted surgery (RAS) system for use in use in urologic and gynecologic laparoscopic surgical procedures, which make up about half of all robotic procedures performed today. 1

Keep reading... Show less

APMA Grants Seal of Approval for JUBLIA® Topical Solution, 10%

Bausch Health Companies Inc. (NYSETSX: BHC) ("Bausch Health") and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced JUBLIA ® (efinaconazole) Topical Solution, 10%, a treatment for onychomycosis, a fungal infection of the toenails, has received the American Podiatric Medical Association (APMA) Seal of Approval. The APMA Seal of Approval is granted to products that promote good foot health and are of significant value when used in a consistently applied program of daily foot care and regular professional treatment.

Keep reading... Show less

Johnson & Johnson COVID-19 Booster, Administered Six Months After Two-Dose Regimen of BNT162b2, Shows Substantial Increase in Antibody and T-cell Responses

- Johnson & Johnson (NYSE: JNJ) (the Company) today announced preliminary results from an independent study, including a subset of participants from the Janssen-sponsored COV2008 study, conducted by Dan Barouch M.D., Ph.D., et al. of Beth Israel Deaconess Medical Center (BIDMC), which showed that a booster shot of the Johnson & Johnson COVID-19 vaccine (Ad26.COV2.S), administered at six months after a two-dose primary regimen of BNT162b2, increased both antibody and T-cell responses. These results demonstrate the potential benefits of heterologous boosting (mix-and-match). The article describing these results have been posted on medRxiv .

"There is early evidence to suggest that a mix-and-match boosting approach may provide individuals with different immune responses against COVID-19 than a homologous boosting approach," said Dan Barouch , M.D., Ph.D., Director of the Center for Virology and Vaccine Research at BIDMC. "In this preliminary study, when a booster dose of Ad26.COV2.S was given to individuals six months after a primary regimen with the BNT162b2 vaccine, there was a comparable increase of antibody responses at week four following the boost and a greater increase of CD8+ T-cell responses with Ad26.COV2.S compared with BNT162b2."

Keep reading... Show less

Janssen to Showcase Progress on Respiratory Syncytial Virus Vaccine Candidate at ESWI 2021

The Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ) today announced it will present data from six company-sponsored studies in support of their respiratory syncytial virus (RSV) adult vaccine candidate at the Eighth European Scientific Working Group on Influenza (ESWI) meeting . The cornerstone of Janssen's presence at ESWI will be a series of presentations detailing findings from the Phase 2b CYPRESS trial in adults at increased risk for RSV.

Keep reading... Show less

Top News

Related News